Literature DB >> 20639712

Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis.

Christina Keen1, Anna-Carin Olin, Susanne Eriksson, Anna Ekman, Anders Lindblad, Samar Basu, Christopher Beermann, Birgitta Strandvik.   

Abstract

OBJECTIVES: To obtain a balance in the fatty acid (FA) metabolism is important for the inflammatory response and of special importance in cystic fibrosis (CF), which is characterized by impaired FA metabolism, chronic inflammation, and infection in the airways. Nitric oxide (NO) has antimicrobial properties and low nasal (nNO) and exhaled NO (FENO), commonly reported in CF that may affect bacterial status. The present study investigates the effect of different FA blends on nNO and FENO and immunological markers in patients with CF. PATIENTS AND METHODS: Forty-three patients with CF and "severe" mutations were consecutively enrolled in a randomized double-blind placebo-controlled study with 3 FA blends containing mainly n-3 or n-6 FA or saturated FA acting as placebo. FENO, nNO, serum phospholipid concentrations of FA, and biomarkers of inflammation were measured before and after 3 months of supplementation.
RESULTS: Thirty-five patients in clinically stable condition completed the study. The serum phospholipid FA pattern changed significantly in all 3 groups. An increase of the n-6 FA, arachidonic acid, was associated with a decrease of FENO and nNO. The inflammatory biomarkers, erythrocyte sedimentation rate, and interleukin-8 decreased after supplementation with n-3 FA and erythrocyte sedimentation rate increased after supplementation with n-6 FA.
CONCLUSIONS: This small pilot study indicated that the composition of dietary n-3 and n-6 FA influenced the inflammatory markers in CF. FENO and nNO were influenced by changes in the arachidonic acid concentration, supporting previous studies suggesting that both the lipid abnormality and the colonization with Pseudomonas influenced NO in the airways.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20639712     DOI: 10.1097/MPG.0b013e3181b47967

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  6 in total

1.  Effect of Oral Lipid Matrix Supplement on Fat Absorption in Cystic Fibrosis: A Randomized Placebo-Controlled Trial.

Authors:  Virginia A Stallings; Joan I Schall; Asim Maqbool; Maria R Mascarenhas; Belal N Alshaikh; Kelly A Dougherty; Kevin Hommel; Jamie Ryan; Okan U Elci; Walter A Shaw
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-12       Impact factor: 2.839

2.  Omega-3 fatty acid supplementation for cystic fibrosis.

Authors:  Helen Watson; Caroline Stackhouse
Journal:  Cochrane Database Syst Rev       Date:  2020-04-10

Review 3.  Omics approaches in cystic fibrosis research: a focus on oxylipin profiling in airway secretions.

Authors:  Jason P Eiserich; Jun Yang; Brian M Morrissey; Bruce D Hammock; Carroll E Cross
Journal:  Ann N Y Acad Sci       Date:  2012-07       Impact factor: 5.691

Review 4.  Omega-3 fatty acids for cystic fibrosis.

Authors:  Colleen Oliver; Helen Watson
Journal:  Cochrane Database Syst Rev       Date:  2016-01-05

Review 5.  Pathophysiology of cystic fibrosis and drugs used in associated digestive tract diseases.

Authors:  Adriana Haack; Giselle Gonçalves Aragão; Maria Rita Carvalho Garbi Novaes
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

6.  Monoacylglycerol Form of Omega-3s Improves Its Bioavailability in Humans Compared to Other Forms.

Authors:  Bernard Cuenoud; Isabelle Rochat; Maria Laura Gosoniu; Lenaick Dupuis; Evan Berk; Anke Jaudszus; Jochen G Mainz; Gaudenz Hafen; Maurice Beaumont; Cristina Cruz-Hernandez
Journal:  Nutrients       Date:  2020-04-07       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.